STSS
Sharps Technology, Inc.
Medical - Instruments & Supplies
Market Cap$8K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
STSS vs SRTS
Revenue, margins, valuation, and 5-year total return — side by side.
SRTS
Sensus Healthcare, Inc.
Medical - Devices
Market Cap$68M
5Y Perf.-41.8%
STSS vs SRTS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | STSS | SRTS |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $8K | $68M |
| Revenue (TTM) | $223K | $27M |
| Net Income (TTM) | $-723K | $-8M |
| Gross Margin | -7.6% | 43.2% |
| Operating Margin | -40.9% | -37.5% |
| Total Debt | $4M | $680K |
| Cash & Equiv. | $864K | $22M |
STSS vs SRTS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
STSS
SRTS
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Sharps Technology, … (STSS) | 100 | 0.0 | -100.0% |
| Sensus Healthcare, … (SRTS) | 100 | 58.2 | -41.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STSS vs SRTS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRTS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Sharps Technology, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
STSS
Sharps Technology, Inc.
The Growth Leader
STSS is the clearest fit if your priority is growth and efficiency.
- 99.1% revenue growth vs SRTS's -34.3%
- -4.2% ROA vs SRTS's -13.4%, ROIC -120.0% vs -25.3%
Best for: growth and efficiency
SRTS
Sensus Healthcare, Inc.
The Income Pick
SRTS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.93
- Rev growth -34.3%, EPS growth -214.6%, 3Y rev CAGR -14.9%
- -29.7% 10Y total return vs STSS's -100.0%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | STSS | 99.1% revenue growth vs SRTS's -34.3% |
| Quality / Margins | SRTS | -28.1% margin vs STSS's -324.8% |
| Stability / Safety | SRTS | Beta 0.93 vs STSS's 2.56, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SRTS | -2.6% vs STSS's -59.9% |
| Efficiency (ROA) | STSS | -4.2% ROA vs SRTS's -13.4%, ROIC -120.0% vs -25.3% |
STSS vs SRTS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
STSS vs SRTS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSRTSLAGGINGSTSS
STSSSharps Technology, In…
0leads
SRTSSensus Healthcare, In…
4leads
6 Total Categories
CATEGORYLEADERvs STSSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SRTS4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SRTS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SRTS6/6
Risk & VolatilityBeta, volatility, and downside exposure
SRTS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SRTS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRTS is the larger business by revenue, generating $27M annually — 123.4x STSS's $222,722. Profitability is closely matched — net margins range from -28.1% (SRTS) to -3.2% (STSS).
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| RevenueTrailing 12 months | $222,722 | $27M |
| EBITDAEarnings before interest/tax | -$8M | -$10M |
| Net IncomeAfter-tax profit | -$723,347 | -$8M |
| Free Cash FlowCash after capex | -$10M | $449,000 |
| Gross MarginGross profit ÷ Revenue | -7.6% | +43.2% |
| Operating MarginEBIT ÷ Revenue | -40.9% | -37.5% |
| Net MarginNet income ÷ Revenue | -3.2% | -28.1% |
| FCF MarginFCF ÷ Revenue | -44.2% | +1.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -62.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +111.0% | -3.0% |
SRTS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — STSS and SRTS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| Market CapShares × price | $7,830 | $68M |
| Enterprise ValueMkt cap + debt − cash | $3M | $46M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -8.74x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.46x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.40x |
| Price / FCFMarket cap ÷ FCF | — | 203.79x |
Evenly matched — STSS and SRTS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SRTS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
STSS delivers a -5.0% return on equity — every $100 of shareholder capital generates $-5 in annual profit, vs $-15 for SRTS. SRTS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to STSS's 1.89x. On the Piotroski fundamental quality scale (0–9), SRTS scores 4/9 vs STSS's 3/9, reflecting mixed financial health.
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| ROE (TTM)Return on equity | -5.0% | -15.1% |
| ROA (TTM)Return on assets | -4.2% | -13.4% |
| ROICReturn on invested capital | -120.0% | -25.3% |
| ROCEReturn on capital employed | -153.7% | -19.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 1.89x | 0.01x |
| Net DebtTotal debt minus cash | $3M | -$21M |
| Cash & Equiv.Liquid assets | $864,041 | $22M |
| Total DebtShort + long-term debt | $4M | $680,000 |
| Interest CoverageEBIT ÷ Interest expense | -0.20x | — |
SRTS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SRTS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SRTS five years ago would be worth $12,088 today (with dividends reinvested), compared to $1 for STSS. Over the past 12 months, SRTS leads with a -2.6% total return vs STSS's -59.9%. The 3-year compound annual growth rate (CAGR) favors SRTS at 11.3% vs STSS's -92.9% — a key indicator of consistent wealth creation.
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| YTD ReturnYear-to-date | -16.5% | +0.2% |
| 1-Year ReturnPast 12 months | -59.9% | -2.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | +37.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | +20.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -29.7% |
| CAGR (3Y)Annualised 3-year return | -92.9% | +11.3% |
SRTS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SRTS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SRTS is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than STSS's 2.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SRTS currently trades 69.4% from its 52-week high vs STSS's 10.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.56x | 0.93x |
| 52-Week HighHighest price in past year | $18.23 | $5.92 |
| 52-Week LowLowest price in past year | $1.42 | $3.03 |
| % of 52W HighCurrent price vs 52-week peak | +10.3% | +69.4% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 49.8 |
| Avg Volume (50D)Average daily shares traded | 327K | 54K |
SRTS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | STSSSharps Technology… | SRTSSensus Healthcare… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
SRTS leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallSensus Healthcare, Inc. (SRTS)Leads 4 of 6 categories
Loading custom metrics...
STSS vs SRTS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — STSS or SRTS?
Over the past 5 years, Sensus Healthcare, Inc.
(SRTS) delivered a total return of +20. 9%, compared to -100. 0% for Sharps Technology, Inc. (STSS). Over 10 years, the gap is even starker: SRTS returned -29. 7% versus STSS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — STSS or SRTS?
By beta (market sensitivity over 5 years), Sensus Healthcare, Inc.
(SRTS) is the lower-risk stock at 0. 93β versus Sharps Technology, Inc. 's 2. 56β — meaning STSS is approximately 173% more volatile than SRTS relative to the S&P 500. On balance sheet safety, Sensus Healthcare, Inc. (SRTS) carries a lower debt/equity ratio of 1% versus 189% for Sharps Technology, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — STSS or SRTS?
On earnings-per-share growth, the picture is similar: Sensus Healthcare, Inc.
grew EPS -214. 6% year-over-year, compared to -782. 0% for Sharps Technology, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — STSS or SRTS?
Sensus Healthcare, Inc.
(SRTS) is the more profitable company, earning -28. 1% net margin versus -324. 8% for Sharps Technology, Inc. — meaning it keeps -28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRTS leads at -37. 5% versus -40. 9% for STSS. At the gross margin level — before operating expenses — SRTS leads at 43. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — STSS or SRTS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is STSS or SRTS better for a retirement portfolio?
For long-horizon retirement investors, Sensus Healthcare, Inc.
(SRTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93)). Sharps Technology, Inc. (STSS) carries a higher beta of 2. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRTS: -29. 7%, STSS: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between STSS and SRTS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.